Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MariMed Inc. filings document formal disclosures for a cannabis consumer products and retail operator, including annual-meeting governance, operating results and material capital-structure agreements. Recent Form 8-K reports furnish quarterly and annual financial results and describe the restructuring of the company's Series B Convertible Preferred Stock obligation, including related debt and equity components.
Proxy materials disclose stockholder meeting procedures and board-governance matters. The filings also identify MariMed's emerging growth company status and provide public records for transactions, obligations and reporting events connected to its cannabis brand, wholesale distribution and dispensary operations.
MariMed Inc. Chief Commercial Officer Ryan Crandall reported equity compensation activity involving restricted stock units (RSUs) that convert to common shares on a one-for-one basis. On the reported date, 12,500 RSUs were exercised into 12,500 shares of common stock at no cash exercise price.
To satisfy tax withholding obligations tied to this RSU vesting, 4,332 common shares were withheld by the company. After these transactions, Crandall’s direct ownership in MariMed common stock stood at 875,683 shares.
MARIMED INC. Chief Operating Officer Timothy Shaw reported equity compensation activity involving restricted stock units (RSUs) and common shares. On March 1, 2026, 65,000 RSUs were exercised, converting on a one-for-one basis into 65,000 shares of common stock at a stated price of $0.0000 per share.
To cover tax withholding obligations tied to this RSU vesting, 22,523 shares of common stock were withheld by the company at $0.0848 per share, reducing the net shares retained. After these transactions, Shaw directly held 9,337,018 shares of MARIMED common stock.
The filing also notes 2,000,000 shares of common stock held indirectly by the Shaw Family Trust. Shaw’s spouse is the trustee, and the trust benefits their children; Shaw disclaims beneficial ownership of these trust-held securities. The RSUs involved were granted on September 1, 2023, with remaining units scheduled to vest on September 1, 2026 under an award agreement.
MariMed Inc. entered into a restructuring agreement with Navy Capital that cancels its prior Series B preferred stock obligation tied to a potential cash payment of approximately $14.2 million. In its place, MariMed issued two new promissory notes totaling $8,000,000 and new Series B preferred shares.
The notes comprise $2,000,000 due on March 1, 2028 at 8% interest and $6,000,000 due on March 1, 2031 at 10%, with a possible rate reduction if the first note is repaid within six months. MariMed also issued 26,900,000 non-voting New Series B Convertible Preferred shares with a liquidation preference of $6,725,000 that rank senior to common stock for dividends and liquidation and are convertible into common stock under specified price and VWAP conditions.
MariMed Inc. Chief Financial Officer Mario Pinho reported routine equity award activity. On January 15, 2026, 49,995 restricted stock units converted into 49,995 shares of common stock at a price of $0 per share, increasing his directly held common stock to 294,809 shares. As part of the same vesting event, 17,324 common shares were withheld by MariMed at $0.096 per share to satisfy tax withholding obligations, leaving Pinho with 277,485 common shares held directly after the withholding.
The underlying restricted stock unit award was originally granted on July 15, 2024 and continues to vest over time, with remaining installments scheduled on July 15, 2026, January 15, 2027 and July 15, 2027. Following this transaction, Pinho directly holds 149,985 restricted stock units, each convertible into one share of common stock.
MariMed Inc.'s Chief Financial Officer reported equity compensation activity involving restricted stock units (RSUs) that vested and converted into common shares. On 12/31/2025, 53,571 RSUs were converted into the same number of shares of common stock at an effective price of $0, increasing his directly held position to 260,538 shares. On the same date, 15,724 shares were withheld and disposed of at $0.0891 per share to cover tax obligations tied to the vesting, leaving the officer with 244,814 directly owned shares afterward. The RSU grant, originally awarded on February 18, 2025, is now fully vested with no remaining unvested units.
MariMed Inc. director Eva Selhub reported an equity compensation transaction involving restricted stock units (RSUs). On December 15, 2025, 166,985 RSUs converted into the same number of shares of MariMed common stock at a stated price of $0, reflecting the non-cash nature of the award. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 under an award agreement between MariMed and Selhub. According to the filing, these RSUs were granted in lieu of cash for a portion of her fees for serving on the Board of Directors, and she beneficially owned 482,671 shares of common stock directly after the transaction.
MariMed Inc.'s Chief Financial Officer, Mario Pinho, reported equity award activity involving restricted stock units (RSUs) and common shares. On December 15, 2025, 16,075 RSUs were converted into the same number of shares of common stock at a stated price of $0, reflecting the vesting of a stock-based award.
To cover tax withholding obligations from this vesting, 4,719 shares of common stock were withheld by MariMed at a price of $0.1071 per share. After these transactions, Pinho directly owned 206,967 shares of MariMed common stock. All RSUs from the May 9, 2025 grant are now fully vested, with no unvested units remaining under that award.
MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported insider equity activity dated 12/15/2025. On that date, 89,859 restricted stock units vested and converted one-for-one into shares of common stock at a stated price of $0, increasing his direct holdings.
To satisfy related tax withholding obligations, 26,374 shares of common stock were withheld by MariMed at $0.1071 per share. Following these entries, Levine directly holds 21,136,200 MariMed common shares and has indirect beneficial ownership of 6,684,640 shares held by the Jon Levine Family Trust for the benefit of his spouse and children, which he formally disclaims for Section 16 purposes.
MariMed Inc. director Edward Gildea reported the conversion of restricted stock units into common stock. On December 15, 2025, 247,385 restricted stock units were settled into 247,385 shares of MariMed common stock at a stated price of $0 per share under transaction code M.
After this transaction, Gildea directly owned 905,208 shares of MariMed common stock. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 as payment in stock instead of cash for a portion of his fees for serving on the company’s board of directors.
MariMed Inc.'s Chief Commercial Officer Ryan Crandall reported stock-based compensation and related share movements dated December 15, 2025. He converted previously granted restricted stock units (RSUs) into 62,902 shares of common stock at a stated price of $0, and 18,462 shares were withheld to cover tax obligations, leaving him with 867,515 common shares held directly after the transactions.
On the same date, Crandall received a new grant of 1,000,000 RSUs, each convertible into one share of MariMed common stock. These RSUs were issued in lieu of a cash salary increase tied to his promotion to Chief Commercial Officer and will vest in four equal installments on June 15, 2026, December 15, 2026, June 15, 2027 and December 15, 2027.